MeiraGTx Holdings PLC
MGTX7.770USD
+0.120+1.57%
Horário de mercado （ET）Cotações atrasadas em 15 min
617.08MValor de mercado
PerdaP/L TTM
Mais detalhes de MeiraGTx Holdings PLC Empresa
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Informações da empresa
Código da empresaMGTX
Nome da EmpresaMeiraGTx Holdings PLC
Data de listagemJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Número de funcionários381
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 08
Endereço450 East 29Th Street
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10016
Telefone16468607985
Sitehttps://meiragtx.com/
Código da empresaMGTX
Data de listagemJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 4 de jun
Atualizado em: qua, 4 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
Investidores
Investidores
Proporção
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
Tipos de investidores
Investidores
Proporção
Hedge Fund
21.86%
Corporation
20.11%
Private Equity
15.65%
Venture Capital
8.26%
Investment Advisor
7.44%
Investment Advisor/Hedge Fund
5.60%
Individual Investor
4.27%
Research Firm
0.89%
Pension Fund
0.08%
Other
15.83%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
230
67.81M
84.38%
+4.14M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Perceptive Advisors LLC
12.58M
15.65%
--
--
Mar 31, 2025
Sanofi SA
12.20M
15.18%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.63M
7.01%
+600.00K
+11.92%
Mar 31, 2025
Prosight Capital
3.69M
4.59%
-699.29K
-15.93%
Mar 31, 2025
Adena Estate Inc.
3.27M
4.06%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.73M
3.39%
+87.69K
+3.32%
Mar 31, 2025
683 Capital Management LLC
2.58M
3.2%
+160.00K
+6.63%
Mar 31, 2025
Rubric Capital Management LP
1.78M
2.21%
+1.78M
--
Mar 31, 2025
Forbes (Alexandria)
1.41M
1.75%
-47.50K
-3.26%
Apr 08, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver Mais
iShares Micro-Cap ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.06%
Invesco Nasdaq Biotechnology ETF
Proporção0.06%
Goldman Sachs Innovate Equity ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.04%
SPDR S&P International Small Cap ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
